Nuvalent, Inc.: management transactions · United States · SEC (Form 4)

About Nuvalent, Inc.

Nuvalent, Inc. is a United States-based biopharmaceutical company listed on the NASDAQ under the ticker NUVL. Headquartered in Cambridge, Massachusetts, it is focused on precision oncology and, more specifically, on the development of highly selective kinase inhibitors for genetically defined subsets of non-small cell lung cancer (NSCLC). The company was founded in the early 2020s and has built its strategy around a relatively narrow but scientifically demanding thesis: design small molecules that can improve upon existing targeted therapies by addressing resistance, limiting off-target toxicity, and better penetrating the central nervous system. Nuvalent remains a clinical-stage company, so its value proposition is still driven primarily by pipeline execution rather than commercial sales. ([investors.nuvalent.com](https://investors.nuvalent.com/2026-04-07-Nuvalent-Announces-Submission-of-New-Drug-Application-to-FDA-for-Neladalkib-in-TKI-Pre-treated-Advanced-ALK-positive-NSCLC?utm_source=openai)) Its core pipeline is built around three main programs: zidesamtinib (NVL-520), a ROS1-selective inhibitor; neladalkib (NVL-655), an ALK-selective inhibitor; and NVL-330, a HER2-selective inhibitor. The company also has multiple discovery-stage research programs. From an investor perspective, this makes Nuvalent a focused oncology platform rather than a diversified pharmaceutical business. Its competitive position is based on structure-guided design and unusually high target selectivity, with the goal of serving patients whose disease has become resistant to prior kinase inhibitors or who need therapies with better tolerability and more durable responses. ([investors.nuvalent.com](https://investors.nuvalent.com/overview?utm_source=openai)) Nuvalent’s geographic footprint is concentrated in the United States, where its corporate base, clinical operations and investor relations functions are centered, although its trials and development programs are global in scope. The company’s recent news flow has been materially positive. On April 7, 2026, Nuvalent announced submission of an NDA to the U.S. FDA for neladalkib in TKI-pretreated advanced ALK-positive NSCLC, supported by data from the ALKOVE-1 phase 1/2 trial. In May 2026, the company also stated that zidesamtinib was under FDA review with a PDUFA target date, highlighting that at least two lead programs had advanced to late-stage regulatory inflection points. In addition, Nuvalent’s investor materials emphasize continued pipeline momentum and multiple expected milestones, which is important for assessing clinical and regulatory execution risk. ([investors.nuvalent.com](https://investors.nuvalent.com/2026-04-07-Nuvalent-Announces-Submission-of-New-Drug-Application-to-FDA-for-Neladalkib-in-TKI-Pre-treated-Advanced-ALK-positive-NSCLC?utm_source=openai))